Clinical Trials Directory

Trials / Unknown

UnknownNCT01642706

Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments

Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments

Status
Unknown
Phase
—
Study type
Observational
Enrollment
240 (estimated)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans.

Detailed description

B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been identified in humans. Main objective: To study Bregs abnormalities in patients with rheumatoid arthritis (RA) at different stages of the disease compared to subjects with mechanical pathologies.Secondary objectives:- To evaluate the specificity of any abnormalities identified in RA by studying Bregs in patients with other autoimmune or other inflammatory joint diseases.- To evaluate the effect of biological and synthetic treatments on Bregs in patients with RA. - To assess whether the rate of Bregs before treatment is predictive of response to biological and synthetic treatments.

Conditions

Timeline

Start date
2012-07-02
Primary completion
2020-12-01
Completion
2020-12-01
First posted
2012-07-17
Last updated
2020-07-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01642706. Inclusion in this directory is not an endorsement.